Literature DB >> 23660863

SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis.

Ulrich Lehmann, Stephan Bartels, Britta Hasemeier, Robert Geffers, Jerome Schlue, Guntram Büsche, Kais Hussein, Hans Kreipe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23660863     DOI： 10.1182/blood-2012-11-467662

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2.

Authors:  S Bartels; M Faisal; G Büsche; J Schlue; H Kreipe; U Lehmann
Journal:  Leukemia       Date:  2017-09-22       Impact factor: 11.528

Review 2.  [Diagnostic molecular pathology of lymphatic and myeloid neoplasms].

Authors:  W Klapper; H Kreipe
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

3.  SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation.

Authors:  S Bartels; U Lehmann; G Büsche; J Schlue; M Mozer; J Stadler; I Triviai; H Alchalby; N Kröger; H Kreipe
Journal:  Leukemia       Date:  2014-09-18       Impact factor: 11.528

Review 4.  Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.

Authors:  Stephan Bartels; Elisa Schipper; Britta Hasemeier; Hans Kreipe; Ulrich Lehmann
Journal:  Oncotarget       Date:  2016-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.